Quick answer
A wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.1 This is an exploratory analysis intended to help design future trials, not to confirm a treatment effect.1 For Filipino readers, the useful next step is to keep that finding tied to the cited study and verify any local product claim separately.
What is SS-31, in plain language?
For readers following SS-31 study on Identifying responders elamipretide Barth, the order matters: identify the study setting, read the result, then place the limitation beside it.
The source describes a focused result: a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.1
The population and method are part of the answer: this analysis used data from the 12-patient randomized crossover trial to see if continuous physiological data could identify treatment responders.1
The source also narrows the conclusion: this is an exploratory analysis intended to help design future trials, not to confirm a treatment effect.1
Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.
What did the central study report?
A result becomes easier to trust when the SS-31 study on Identifying responders elamipretide Barth details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.
The paper’s main result was that in a phase 3 trial of 218 adults with primary mitochondrial myopathy (PMM), elamipretide did not significantly improve the 6-minute walk distance or total fatigue score compared to placebo over 24 weeks.2
The study context keeps the conclusion precise: this was the MMPOWER-3 randomized, double-blind, placebo-controlled trial. The primary endpoints were not met.2
What does the wider evidence add?
The practical reading of SS-31 study on Identifying responders elamipretide Barth is specific rather than dramatic. Keep the measured outcome, the comparison, and the study setting attached to one another.
The central finding was specific: a post hoc analysis of the MMPOWER-3 trial found that a subgroup of patients with nuclear DNA (nDNA) defects in the mtDNA replisome showed a trend toward improvement on the 6-minute walk test with elamipretide.3
That result came from this context: this was a post hoc analysis, meaning it was planned after the trial concluded. The improvement of 25.2 meters versus 2.0 meters for placebo had a p-value of 0.06.3
The finding should stop here: post hoc analyses are considered exploratory and cannot prove a treatment effect on their own.3
Which limits matter most?
The useful question in this SS-31 study on Identifying responders elamipretide Barth story is not whether the headline sounds impressive. It is whether the population, outcome, and comparison still match the cited source.
The source describes a focused result: a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.1
The population and method are part of the answer: this analysis used data from the 12-patient randomized crossover trial to see if continuous physiological data could identify treatment responders.1
The source also narrows the conclusion: this is an exploratory analysis intended to help design future trials, not to confirm a treatment effect.1
How does the catalog identity fit?
For readers following SS-31 study on Identifying responders elamipretide Barth, the order matters: identify the study setting, read the result, then place the limitation beside it.
The paper’s main result was that in a long-term open-label extension of the TAZPOWER trial, patients with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the 6-minute walk test at the 168-week visit.4
The study context keeps the conclusion precise: this was a 168-week open-label extension following a 28-week randomized trial. Ten patients entered the extension, and eight completed it.4
That result does not erase its main limit: open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations.4
The study reported that the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.5 The main limit is equally important: a portal record applies to the exact product or establishment named in that record.5
Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.
What should Filipino readers take away?
A result becomes easier to trust when the SS-31 study on Identifying responders elamipretide Barth details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.
The central finding was specific: within that replisome subgroup, patients who also had chronic progressive external ophthalmoplegia (CPEO) showed a significant 37.3-meter improvement on the 6-minute walk test with elamipretide compared to a decline in the placebo group.6
That result came from this context: this was a further analysis of the MMPOWER-3 trial data, focusing on a specific clinical presentation within the nDNA replisome subgroup.6
The finding should stop here: this finding comes from a very specific, small subgroup and requires confirmation in a prospective trial.6
Researchers found that WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.7 One caution belongs beside that result: appearance alone cannot authenticate a product or establish a research outcome.7
Bottom line
The clearest reading is that a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.1
Open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations.4 For Filipino readers, the research result and the exact local product record remain separate checks.
That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.
Frequently asked questions
What is the short answer about SS-31?
The cited source gives a focused answer: a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.1 The conclusion stays tied to that study’s population, method, and measured outcome.
Does one positive result settle the whole topic?
No. Open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations.4 A useful result can remain narrow without being dismissed or promoted as a universal benefit.
Why does the study context matter?
This was the MMPOWER-3 randomized, double-blind, placebo-controlled trial. The primary endpoints were not met.2 Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.
What should Filipino readers verify?
In a long-term open-label extension of the TAZPOWER trial, patients with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the 6-minute walk test at the 168-week visit.4 Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.
Do the SS-31 and MOTS-C cards prove a benefit?
No. In this SS-31 study on Identifying responders elamipretide Barth guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.8
Sources
Footnotes
-
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.. This analysis used data from the 12-patient randomized crossover trial to see if continuous physiological data could identify treatment responders. This is an exploratory analysis intended to help design future trials, not to confirm a treatment effect. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10
-
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. This was the MMPOWER-3 randomized, double-blind, placebo-controlled trial. The primary endpoints were not met. ↩ ↩2 ↩3
-
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. This was a post hoc analysis, meaning it was planned after the trial concluded. The improvement of 25.2 meters versus 2.0 meters for placebo had a p-value of 0.06. Post hoc analyses are considered exploratory and cannot prove a treatment effect on their own. ↩ ↩2 ↩3
-
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. This was a 168-week open-label extension following a 28-week randomized trial. Ten patients entered the extension, and eight completed it. Open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations. ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩2
-
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. This was a further analysis of the MMPOWER-3 trial data, focusing on a specific clinical presentation within the nDNA replisome subgroup. This finding comes from a very specific, small subgroup and requires confirmation in a prospective trial. ↩ ↩2 ↩3
-
WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩2
-
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩
